Cyclosporin promotes neurorestoration and cell replacement therapy in pre-clinical models of Parkinson's disease.

Research output: Contribution to journalArticle

Abstract

The early clinical trials using fetal ventral mesencephalic (VM) allografts in Parkinson's disease (PD) patients have shown efficacy (albeit not in all cases) and have paved the way for further development of cell replacement therapy strategies in PD. The preclinical work that led to these clinical trials used allografts of fetal VM tissue placed into 6-OHDA lesioned rats, while the patients received similar allografts under cover of immunosuppression in an α-synuclein disease state. Thus developing models that more faithfully replicate the clinical scenario would be a useful tool for the translation of such cell-based therapies to the clinic.

Details

Authors
  • Anna Tamburrino
  • Madeline J Churchill
  • Oi Wan Wan
  • Yolanda Colino Sanguino
  • Rossana Ippolito
  • Sofie Bergstrand
  • Daniel Wolf
  • Niculin J Herz
  • Michelle D Sconce
  • Anders Björklund
  • Charles K Meshul
  • Mickael Decressac
Organisations
External organisations
  • Telethon Institute of Genetics and Medicine
  • Oregon Health & Science University
  • Jan and Dan Duncan Neurological Research Institute
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Neurosciences
Original languageEnglish
Article number84
JournalActa neuropathologica communications
Volume3
Issue number1
Publication statusPublished - 2015 Dec 14
Publication categoryResearch
Peer-reviewedYes